Speakers

Expand/Collapse

Neeraj Agrawal
Senior Scientist, Group Lead of Attribute Science Data Engineering
Amgen

Day Two

Wednesday November 21, 2019

4:45 pm | The Real Value & Opportunities in End-to-End Computational Drug Development for Biologics

Sandeep Kumar
Senior Research Fellow (Biotherapeutics) & Group Leader
Boehringer Ingelheim

Day Two

Wednesday November 21, 2019

4:15 pm | Biopharmaceutical Informatics: A Unified Approach to Biologic Drug Design, Discovery & Development

Andrew Urick
Senior Scientist
Abbvie

His works focus on:

  • Interface computational modeling with high-throughput robotics platforms to engineer biologics with improved structural properties
  • Design and implement biophysical screening workflows to assess protein structure and function

Day One

Tuesday November 20, 2019

4:30 pm | Interfacing Computational Modeling with Biophysical Characterization to Guide High-Throughput Protein Engineering

Brandon DeKosky
Assistant Professor - Chemical Engineering & Pharmaceutical Chemistry
University of Kansas

​The DeKosky laboratory works to invent and apply advanced NextGen molecular biology techniques to accelerate development of new human vaccines and therapeutics.  We have a special focus on understanding highly effective human antibody responses to persistent viral infections (including HIV, EBV, CMV), and in characterizing the antibody response to experimental vaccines. Postdoctoral, Immunology & Vaccinology, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD (2017) Ph.D., Biochemical Engineering, University of Texas, Austin (2015) B.S., Chemical Engineering, University of Kansas, Lawrence (2010)

Day One

Tuesday November 20, 2019

2:45 pm | High-Throughput Antibody Functional Data Analyses to Enhance Drug Discovery

Brian Pierce
Assistant Professor
IBBR University of Maryland

Brian Pierce is Assistant Professor at Institute for Bioscience and Biotechnology Research. Prior to this he was Research Assistant Professor at UMass Medical School where his work focused on modeling and affinity improvement of protein-protein interactions, computational structural immunology, structure-based design of immunotherapeutics and vaccines.

Day One

Tuesday November 20, 2019

9:45 am | Modelling & Structure-Based Design of Antibody & T cell Receptor Recognition

Chris Roberts
Professor - Chemical & Biomolecular Engineering
University of Delaware

Christopher J. Roberts is a Professor in the Department of Chemical and Biomolecular Engineering at the University of Delaware (UD). He is the Associate Institute Director for the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL), and the Director of the Biomolecular Interaction Technology Center (BITC). He received a Bachelors of Chemical Engineering degree from UD, and a Ph.D. in Chemical Engineering from Princeton University. Prior to joining UD in 2002, he worked in the pharmaceutical industry as a formulation scientist for protein and small-molecule based drugs. The Roberts laboratory focuses on experimental and theoretical fundamentals and applications of protein physical and chemical stability, (mis)folding, aggregation, statistical mechanics, and kinetics to address questions of biopharmaceutical product design, stability, and manufacturing.

Day Two

Wednesday November 21, 2019

9:15 am | Developing a Suite of Coarse-Grained Molecular Models for Protein Candidate Selection

Claire Marks
Research Software Engineer
University of Oxford

Claire Marks is a researcher based in the Department of Statistics at the University of Oxford. She is a member of the Oxford Protein Informatics Group (OPIG), supervised by Prof. Charlotte Deane. She is the group's lead Research Software Engineer - her main job is maintaining the suite of antibody tools, known the SAbDab-SAbPred platform. She is responsible for facilitating in-house installation of this platform for any pharmaceutical companies wishing to use them, and also look after our web servers.

Day One

Tuesday November 20, 2019

1:45 pm | How Repertoire Data is Changing Antibody Science

Costas Maranas
Professor, Department of Chemical Engineering
The Pennsylvania State University

The C. Maranas group develops and deploys computational framework informed by systems engineering and mathematical optimization to understand, analyze and redesign metabolism and proteins. Research interests include: Computational protein design; enzyme and antibody engineering; design of protein pores for bioseparations; reconstruction, curation and analysis of metabolic networks; computational strain design and synthetic biology; metabolism of photosynthetic organisms; metabolism of obligatory anaerobes; modeling of microbial communities; optimization theory and algorithms.

Day Two

Wednesday November 21, 2019

9:45 am | Computational Design of Antibodies Against Spike Epitopes of SARS-CoV-2

Daniel Vallejo
Graduate Student Research Assistant
University of Michigan

Daniel Vallejo is a Graduate Research Assistant for Dr. Brandon Ruotolo at the University of Michigan. His research focuses around: -Development of high-throughput workflows for biotherapeutic characterization. -Advancement of fundamental mass spectrometry knowledge on physio-chemical processes. -Development of correlation libraries between gas-phase and solution-phase protein structural stability.

Day One

Tuesday November 20, 2019

2:15 pm | The Role of Structural Mass Spectrometry in the Discovery & Development of Therapeutic Antibodies

Dea Shahinas
CEO
Deep Biologics

Senior Research Scientist with academic and industry expertise in computational biology, drug and biologics development. Results driven with proven record in team management, collaboration projects, effective execution and completion of various complex projects with demonstrated proof of concept. Strong analytical, verbal and written communication skills.

Day Two

Wednesday November 21, 2019

2:15 pm | On-Application Technology Advantage of Computational Design: a COVID-19 Example

Ho Leung Ng
Associate Professor - Biochemistry & Molecular Biophysics
Kansas State University

Our lab studies the atomic structure of proteins and ligands using computational and experimental approaches. Our primary tools are computational chemistry, machine learning, and X-ray crystallography. We apply our knowledge of structure to help design drugs, deepen understanding of protein structure and function, and address fundamental questions of protein engineering. Our lab also develops new techniques for the analysis of X-ray crystallographic data. We strive to be the best at research and teaching at Kansas State University.  

Day Two

Wednesday November 21, 2019

1:45 pm | Generative Machine Learning for Design of Peptides & Peptidomimetics

Hyelim Cho
Senior Scientist
Takeda Pharmaceutical

Hyelim is a viral immunologist by training and currently works as a group lead in the global DMPK at Takeda Pharmaceuticals. Her group is developing methods for pre-clinical immunogenicity risk assessment and designing translational bioassays for the regulatory filing effort specifically related to oncology, GI, and rare diseases.  

Jeremy Schmit
Associate Professor
Kansas State University

Jeremy Schmit is Associate Professor at Kansas State University His areas of specialty include:

  • Theoretical Soft Condensed Matter and Biological Physics
  • Protein phase behavior
  • Protein crystallization
  • Amyloid fibril formation
  • Drug formulations
  • Self-assembly

Day Two

Wednesday November 21, 2019

11:30 am | The Many-Body Physics of Antibody Formulation

Klaus Liedl
Professor & Head of the Institute of General, Inorganic & Theoretical Chemistry
University of Innsbruck

Klaus is Full Professor, Chair of Theoretical Chemistry Head of the Institute of General, Inorganic and Theoretical Chemistry at University Innsbruck His research interests include:

  • Structure and dynamics of biomolecular systems
  • Drug development (drug design)
  • Intellectual property rights (patent law)

Day One

Tuesday November 20, 2019

5:00 pm | Antibodies Exhibit Multiple Paratope States Influencing VH-VL Domain Orientations

Maria Wendt
Head of Biologics Research
Sanofi

Maria Wendt is Head of Biologics Research US at Sanofi. Prior to this she was founding principal scientist (2008) of Genedata Biologics® and Genedata Bioprocess® platforms. GDBx and GDBp are global, foundational, enterprise data management, workflow support and data analysis platforms supporting end-to-end biologics research and development processes in large pharmaceutical and biotech organizations worldwide.

Day One

Tuesday November 20, 2019

8:45 am | Digital Transformation in Big Pharma Biologics Drug Discovery & Development

Monica Wang
Principal Engineer, Bioinformatics Architect, Project Program Management & Global Information Technology Lead
Takeda Pharmaceutical

Monica currently leads the Biology (including Biologics) Capabilities and Products in Takeda Scientific Informatics. She has multidiscipline education with PhD in Biochemistry and MSc in Software Engineering. She has 8+ years of experience in academic research and 15+ years of experience in Research Informatics in the biotechnology and pharmaceutical industries. She is good at strategic planning with proven successful track records of managing complicated global enterprise informatics projects. She has delivered many informatics projects within time and budget for many departments (Global Biologics, Molecular Pathology, Protein Science, Biotherapeutics, Translational Medicine and Legal IP et al). She is technically and scientifically proficient in Bioinformatics, Cheminformatics, Functional Genomics, and Pharmacogenomics. Her team has designed and implemented many global enterprise informatics solutions to support research, biomarker discovery, translational and personalized medicine. Her recent focus is concentrated on building a state-of-art Global Biologics Platform to support the global biologics R&D research across Takeda.

Nicolas Angell
Director - Process Development & Pre-Pivotal Attribute Sciences
Amgen

I guide the support of protein therapeutics predictive modeling and manage product quality, process reagent, process impurity, and high-order structure teams and initiatives. In addition, I participate on cross-functional research teams for biologic and synthetic modalities. I lead pre-pivotal product delivery teams to advance therapeutic from discovery research to process development, and from the pre-clinical phase to investigative new drug (IND) filing, and I am responsible for product impact assessments, quality target product profiles (QTPPs), product test and release methods, and process improvement. Also, I design and manage the strategy and execution of novel disruptive technologies, including chemical modification, bioinformatics-driven design, and machine learning, and prepare regulatory filings for U.S. and foreign agencies. Selected Accomplishments: • Successfully delivered all pre-pivotal attribute sciences commitments, including advancement of the polymodal portfolio to IND filings. • Led the development of analytical testing strategies and analytical methodologies for drug substance, drug product, and device process development. • Guided teams in the delivery of data to support product stability, specification development, and product characterization to better understand product attributes. • Improved time-to-patient by developing long-term attribute strategies based on quality by design principles.

Day One

Tuesday November 20, 2019

11:00 am | PANEL DISCUSSION: Where Can Computational Tools Have the Most Impact in Biologics?

Norbert Furtmann
Section Head Data Science & Computational Design, Biologics Research
Sanofi

Norbert Furtmann is Section Head Data Science & Computational Design at Sanofi. He is responsible for Biologics Research and Protein Therapeutics. Prior to his time at Sanofi he was Principal Scientist at Merck Group focused on Analytical Development of NCEs.

Day One

Tuesday November 20, 2019

4:00 pm | Platformization of Multi-Specific Protein Engineering: Learning from High-Throughput Screening Data

Pankaj Agarwal
Principal Computational Biologist
BioInfi

Dr. Pankaj Agarwal, has 22+ years strategic and tactical experience utilizing bioinformatics to enable drug discovery and create pipeline value. He has collaborated extensively with numerous pharmaceutical project teams, academic/biotech partners, and top informatics talent. In 2016, he was among a group of select few scientists appointed as senior fellows at GSK. Dr. Agarwal has also served on NSF, NIH, FDA and PhRMA panels. He possesses a B.Tech. in Computer Science & Engineering from IIT, Delhi and a Ph.D. in Computer Science from the Courant Institute of Mathematical Sciences at NYU. He is a founder and senior member of the International Society for Computational Biology (ISCB). Most importantly, Dr. Agarwal is passionate about drug discovery, rare diseases, and helping patients.

Day One

Tuesday November 20, 2019

9:15 am | Computational Drug Discovery Through Computational Scientific Expert Identification: Data-Driven Recruiting, Organization Building, & Virtual Biotech 2.0

Philip Kim
Professor
University of Toronto

The Kim lab uses and develops computational methods to study protein interactions and signaling networks in the context of cancer and other diseases. We use an integrative approach that encompass structural biophysics, systems biology and comparative genomics. Ultimately, we aim to help develop novel therapies.

Day One

Tuesday November 20, 2019

11:45 am | Design & Screening of Proteins & Antibodies Using Machine Learning

Rafael Depetris
Principal Scientist & Structure Based Drug Design Lead
Kadmon Corporation

Rafael obtained his Ph.D. from NYU in 2008 working with Stevan Hubbard in the field of X-Ray crystallography, specifically focusing on the structural analysis of proteins that interact with the insulin receptor. His post-graduate work was done at Weill Cornell Medical College where he focused in the structural analysis of the HIV-1 Envelope proteins as well as of the HIV-1 neutralizing antibodies. Rafael went on to assume a position of a Senior Scientist at Pfizer CTI in New York, where he initiated his work focused on modeling of targets and therapeutic antibody candidates. He was also commanding the efforts for the humanization of the lead antibody candidates based on the modeling analyses. Rafael is continuing to explore structural features of biologics and their targets in his current position as a Principal Scientist at the Kadmon Corporation in NYC. At Kadmon he is combining his expertise in structural biology with in silico approaches to drive forward discovery projects. He has participated in many symposia, speaking about the interplay of structural analysis and computational tools.

Day One

Tuesday November 20, 2019

11:00 am | PANEL DISCUSSION: Where Can Computational Tools Have the Most Impact in Biologics?

Randal Ketchem
Vice President - Molecular Design
Just Biotherapeutics

Dr. Randal Ketchem received his Ph.D. in Molecular Biophysics from The Florida State University, focusing on experimental protein structure determination, resulting in the first membrane-bound protein structure solved by Solid State NMR. As part of this effort he developed computational methods for the structure calculation and refinement of membrane-bound proteins. Randy continued his training in structural biology in a postdoctoral fellowship at The Scripps Research Institute where he expanded his experimental and computational efforts into solution-based protein structure. Randy then joined Immunex in 1997 to apply his expertise in protein structure modeling and analysis to efforts in the development of biologic-based therapeutics. During his many years of experience at Immunex, Amgen, and Just Biotherapeutics he has led efforts to engineer protein therapeutics, invented novel therapeutic modalities and computational methods for therapeutic design, and developed computational and experimental approaches to understanding and controlling biophysical properties of biological macromolecules. Randy has made significant contributions in antibody design, epitope mapping, molecular assessment, stability engineering, construct design, protein structure analysis, and protein engineering. At Just Randy leads the Molecular Design team, integrating molecular design strategies into the entire therapeutic pipeline.  

Day Two

Wednesday November 21, 2019

12:00 pm | AI-Driven Antibody Diversity to Explore Discovery & Developability

Yao Fan
Principal Research Scientist
Abbvie

Yao Fan is Principal Research Scientist at AbbVie focusing on Biologics Advanced Analytics, Biologics developability assessment and rational biologics design and development. Prior to his time at AbbVie, he was a Senior Scientist at Boehringer Ingelheim focused on technology development for new biotherapeutic molecules and leading project teams for antibody discovery, CMC and early development.

Day One

Tuesday November 20, 2019

11:00 am | PANEL DISCUSSION: Where Can Computational Tools Have the Most Impact in Biologics?

Representative

Schrödinger

Day Two

Wednesday November 21, 2019

11:00 am | Schrödinger Case Study